Sovleplenib is under clinical development by Hutchison MediPharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sovleplenib’s likelihood of approval (LoA) and phase transition for Follicular Lymphoma took place on 29 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 29 Aug 2022 decreased Sovleplenib’s LoA and PTSR for Mantle Cell Lymphoma, decreased LoA and PTSR for Marginal Zone B-cell Lymphoma, decreased LoA and PTSR for Refractory Chronic Lymphocytic Leukemia (CLL), decreased LoA and PTSR for Relapsed Chronic Lymphocytic Leukemia (CLL), and decreased LoA and PTSR for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sovleplenib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sovleplenib overview

Sovleplenib (HMPL-523) is under development for the treatment of hematological cancers such as relapsed and refractory Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, coronavirus disease 2019 (COVID-19), waldenstrom macroglobulinemia, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma and immunological diseases including autoimmune disorder, primary immune thrombocytopenia, Hodgkin and non-Hodgkin lymphoma, marginal zone B-cell lymphoma and autoimmune hemolytic anemia. It is administered orally. The drug candidate targets spleen tyrosine kinase (Syk). It was also under development for acute myeloid leukemia, multiple sclerosis, lupus erythematosus and rheumatoid arthritis. The drug candidate is a new molecular entity (NME).

Hutchison MediPharma overview

Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. It operates through its two offices in Pudong, China. HMPL is headquartered in Pudong, China.

Quick View Sovleplenib LOA Data

Report Segments
  • Innovator
Drug Name
  • Sovleplenib
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.